Zacks Research Issues Negative Forecast for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.34 per share for the quarter, down from their prior forecast of $2.57. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.87 EPS, Q3 2025 earnings at $2.94 EPS and Q3 2026 earnings at $2.90 EPS.

A number of other brokerages also recently weighed in on BIO. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective for the company. Citigroup upped their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada upped their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $332.91 on Friday. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The firm’s fifty day moving average price is $340.52 and its two-hundred day moving average price is $315.93. The firm has a market capitalization of $9.32 billion, a P/E ratio of -12.18 and a beta of 0.93. Bio-Rad Laboratories has a 1 year low of $262.12 and a 1 year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. During the same quarter last year, the company earned $2.33 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 2.8% compared to the same quarter last year.

Institutional Investors Weigh In On Bio-Rad Laboratories

Institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp acquired a new position in shares of Bio-Rad Laboratories in the second quarter worth approximately $180,040,000. First Eagle Investment Management LLC raised its holdings in Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after purchasing an additional 634,311 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter worth approximately $83,681,000. Dimensional Fund Advisors LP boosted its stake in shares of Bio-Rad Laboratories by 64.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after purchasing an additional 193,700 shares during the last quarter. Finally, Select Equity Group L.P. increased its position in shares of Bio-Rad Laboratories by 26.2% during the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after buying an additional 134,856 shares during the period. Institutional investors own 65.24% of the company’s stock.

Insider Buying and Selling

In other news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James Barry sold 623 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.